SPINRAZA™ (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy

- First Treatment Approved for SMA - - SPINRAZA Improved Motor Function in Patients with SMA; Greater Percentage of Infantile-Onset Patients on SPINRAZA Survived - - FDA Approval Received Within 3 Months of Regulatory Filing - CARLSBAD, Calif., Dec. 23, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness. SPINRAZA was discovered and developed by Ionis and Biogen, and licensed to Biogen who is responsible for future development, manufacturing, and commercialization of SPINRAZA.

The release as fetched from its publisher. ionis.com ↗